Vaccine peptide combinations against cat allergy

Abstract

The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides

1 - 23 . (canceled) 
     
     
         24 . A pharmaceutical formulation comprising a pharmaceutically acceptable carrier or diluent, a preservative, and, as the only therapeutic ingredients:
 (I)   a polypeptide which consists of the sequence of SEQ ID NO: 1, a polypeptide which consists of the sequence of SEQ ID NO: 2, a polypeptide which consists of the sequence of SEQ ID NO: 3, a polypeptide which consists of the sequence of SEQ ID NO: 4, a polypeptide which consists of the sequence of SEQ ID NO: 5, a polypeptide which consists of the sequence of SEQ ID NO: 6 and a polypeptide which consists of the sequence of SEQ ID NO: 7   or   (II)   a polypeptide which consists of the sequence of SEQ ID NO: 8, a polypeptide which consists of the sequence of SEQ ID NO: 2, a polypeptide which consists of the sequence of SEQ ID NO: 3, a polypeptide which consists of the sequence of SEQ ID NO: 4, a polypeptide which consists of the sequence of SEQ ID NO: 10, a polypeptide which consists of the sequence of SEQ ID NO: 6 and a polypeptide which consists of the sequence of SEQ ID NO: 7;   or   (III)   a polypeptide which consists of the sequence of SEQ ID NO: 2, a polypeptide which consists of the sequence of SEQ ID NO: 3, a polypeptide which consists of the sequence of SEQ ID NO: 4, a polypeptide which consists of the sequence of SEQ ID NO: 5, a polypeptide which consists of the sequence of SEQ ID NO: 6, a polypeptide which consists of the sequence of SEQ ID NO: 7 and a polypeptide which consists of the sequence of SEQ ID NO: 11; or   (IV)   a polypeptide which consists of the sequence of SEQ ID NO: 2, a polypeptide which consists of the sequence of SEQ ID NO: 3, a polypeptide which consists of the sequence of SEQ ID NO: 4, a polypeptide which consists of the sequence of SEQ ID NO: 5, a polypeptide which consists of the sequence of SEQ ID NO: 6, a polypeptide which consists of the sequence of SEQ ID NO: 7 and a polypeptide which consists of the sequence of SEQ ID NO: 12; or   (V)   a polypeptide which consists of the sequence of SEQ ID NO: 8, a polypeptide which consists of the sequence of SEQ ID NO: 2, a polypeptide which consists of the sequence of SEQ ID NO: 3, a polypeptide which consists of the sequence of SEQ ID NO: 4, a polypeptide which consists of the sequence of SEQ ID NO: 6 and a polypeptide which consists of the sequence of SEQ ID NO: 7; or   (VI)   a polypeptide which consists of the sequence of SEQ ID NO: 8, a polypeptide which consists of the sequence of SEQ ID NO: 2, a polypeptide which consists of the sequence of SEQ ID NO: 3, a polypeptide which consists of the sequence of SEQ ID NO: 4, a polypeptide which consists of the sequence of SEQ ID NO: 6, a polypeptide which consists of the sequence of SEQ ID NO: 7 and a polypeptide which consists of the sequence of SEQ ID NO: 1;   (VII)   a polypeptide which consists of the sequence of SEQ ID NO: 8, a polypeptide which consists of the sequence of SEQ ID NO: 2, a polypeptide which consists of the sequence of SEQ ID NO: 3, a polypeptide which consists of the sequence of SEQ ID NO: 4, a polypeptide which consists of the sequence of SEQ ID NO: 6, polypeptide which consists of the sequence of SEQ ID NO: 7 and a polypeptide which consists of the sequence of SEQ ID NO: 5; or   (VIII)   a polypeptide which consists of the sequence of SEQ ID NO: 8, a polypeptide which consists of the sequence of SEQ ID NO: 2, a polypeptide which consists of the sequence of SEQ ID NO: 3, a polypeptide which consists of the sequence of SEQ ID NO: 4, a polypeptide which consists of the sequence of SEQ ID NO: 6, a polypeptide which consists of the sequence of SEQ ID NO: 7 and a polypeptide which consists of the sequence of SEQ ID NO: 9;   (IX)   a polypeptide which consists of the sequence of SEQ ID NO: 8, a polypeptide which consists of the sequence of SEQ ID NO: 2, a polypeptide which consists of the sequence of SEQ ID NO: 3, a polypeptide which consists of the sequence of SEQ ID NO: 4, a polypeptide which consists of the sequence of SEQ ID NO: 6, a polypeptide which consists of the sequence of SEQ ID NO: 7 and a polypeptide which consists of the sequence of SEQ ID NO: 11; or   (X)   a polypeptide which consists of the sequence of SEQ ID NO: 8, a polypeptide which consists of the sequence of SEQ ID NO: 2, a polypeptide which consists of the sequence of SEQ ID NO: 3, a polypeptide which consists of the sequence of SEQ ID NO: 4, a polypeptide which consists of the sequence of SEQ ID NO: 6, a polypeptide which consists of the sequence of SEQ ID NO: 7 and a polypeptide which consists of the sequence of SEQ ID NO: 12;   wherein:   any polypeptide in each of (I) to (X) may be replaced by a variant or fragment of the replaced polypeptide, provided that at least four said polypeptides are not so replaced, wherein
 (i) a variant of a said polypeptide is up to 30 amino acids in length and comprises the sequence of the said polypeptide; or 
 (ii) a variant of a said polypeptide is up to 30 amino acids in length and comprises or consists of the sequence of said polypeptide in which one, two, three or four amino acid substitutions have been made; and 
 (iii) a fragment of a said polypeptide is at least 9 amino acids in length and comprises the sequence of the said polypeptide in which 1, 2 or 3 amino acids are deleted from the N and/or C terminal ends of the said sequence. 
   
     
     
         25 . The formulation according to  claim 24  in which any polypeptide in each of (I) to (X) may be replaced by a variant or fragment of the replaced polypeptide, provided that at least five or six said polypeptides are not so replaced. 
     
     
         26 . The formulation according to  claim 24  in which any polypeptide in each of (I) to (X) may be replaced by a variant or fragment of the replaced polypeptide, provided that the polypeptides of SEQ ID NOS: 2, 3, 4, 6 and 7 are not so replaced. 
     
     
         27 . The formulation according to  claim 24  in which no polypeptide is replaced by a variant or fragment. 
     
     
         28 . The formulation according to  claim 24  which comprises no further polypeptides. 
     
     
         29 . The formulation according to  claim 24  which is provided as an injectable solution, suspension or emulsion. 
     
     
         30 . The formulation according to  claim 24 , wherein each polypeptide has a concentration in the range of 0.03 to 200 nmol/ml, 0.3 to 200 nmol/ml or 10 to 50 nmol/ml. 
     
     
         31 . The formulation according to  claim 24  which is provided in dry form for reconstitution. 
     
     
         32 . A method of preparing a pharmaceutical formulation as defined in  claim 24 , comprising combining said polypeptides, variants or fragments with a pharmaceutically acceptable carrier or diluent. 
     
     
         33 . A method according to  claim 32  for preparing a composition for parenteral administration comprising providing said polypeptides, variants or fragments in dry form and reconstituting said polypeptides, variants or fragments with a said pharmaceutically acceptable carrier or diluent.